Navigation Links
Sarasota's Roskamp Institute Announces Positive Safety Data in,Human Clinical Study for Alzheimer's Disease

And Japanese Study Suggests the Drug Improves Memory

SARASOTA, Fla., March 22, 2007 /PRNewswire-FirstCall/ -- The Roskamp Institute announced today that it has received positive preliminary results in its major clinical study that is testing a promising new drug application for the treatment of Alzheimer's disease. The clinical study, which was first announced in September, is the first human clinical study conducted by a Florida-based research institute as a result of its own original research. Today's announcement also highlighted achievements with the same drug in studies in Japan.

The drug, Nilvadipine, has not shown any major side effects in Alzheimer's disease patients during the initial six months of the study that is being conducted in partnership with the Trinity College Institute of Neuroscience in Dublin, Ireland. "This is a good indication that this drug will be safe in patients with Alzheimer's disease," said Dr. Michael Mullan, Director of the Roskamp Institute. "A staggering number of drugs fail once they go through their clinical studies due to safety issues. After treating more than a dozen Alzheimer patients with Nilvadipine, we can continue our studies because we have seen no serious side effects related to the drug."

This pilot study was the first step in trying to develop a potential treatment for Alzheimer's disease, and if it continues to be a success, could change the direction of other studies of dementia. In pre-clinical studies on mice, Nilvadipine was found to decrease the levels in the brain of a protein called beta amyloid. It is the presence of beta amyloid in the brain that is believed to cause the onset of Alzheimer's. The drug was also found to increase the flow of blood to the brain, which is believed to be beneficial in the treatment of the disease. The purpose of the study has been to determine whether the drug would have the same effect on humans suffering fro
'"/>




Page: 1 2

Related medicine technology :

1. Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression
2. Actilyse (alteplase) Recommended by National Institute for Health and Clinical Excellence for Treatment of Acute Ischaemic Stroke
3. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
4. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
5. Southern Research Institute to Present at the 2007 American Association For Cancer Research Annual Meeting
6. Protox Announces Publication in Journal of the National Cancer Institute Supporting PRX302 as Treatment for Prostatic Diseases
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:7/22/2014)... 22, 2014  A central New ... temporary Total Artificial Heart implant is home, ... with the Freedom® portable driver to wait for ... 64-year-old retiree from a Syracuse architectural hardware company, ... condition with medications, an implantable defibrillator and a ...
(Date:7/22/2014)... 2014 The Intellectual Property ... the world,s leading provider of intelligent information ... Cortellis Clinical Trials Intelligence , its global ... with the documentation of more than 180,000 ... greater and quicker access to critical data ...
(Date:7/22/2014)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company with operations in China and ... it will release financial results for the second quarter of ... August 13, 2014 (which will be Thursday morning, August 14, ... the investor relations section of the Company,s website at ...
Breaking Medicine Technology:'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 2'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 3Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 2Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 3WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2
... Phase 1 Clinical Trial Results Disclosed, ... Inc., a,biopharmaceutical company developing "Best-in-Class" drugs for ... that the results,of multiple studies on its ... will be presented in eighteen presentations at ...
... CeNeRx BioPharma,Inc., a clinical stage company developing and ... system, today announced that,it has initiated a Phase ... for the treatment of major depressive disorder (MDD). ... novel class of drugs known as RIMAs,or reversible ...
Cached Medicine Technology:Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA 2Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA 3CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM) 2CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM) 3
(Date:7/22/2014)... 22, 2014 CyraCom has been ranked ... in the translation and interpreting industry. Released June 2014 ... report titled "The Language Services Market: 2014," also ranked ... world, moving up two spots from 2013. , In ... LSPs that provide interpretation services – a subset of ...
(Date:7/22/2014)... The Muscular Dystrophy Association (MDA) and Jiffy Lube today ... campaign that will raise funds to help save and ... muscle disease. , As part of the campaign, ... centers through Sept. 1, 2014 to make a donation to ... the fight for muscle health. Since 2012, Jiffy Lube has ...
(Date:7/22/2014)... Paul, Minn. (PRWEB) July 22, 2014 ... dental comfort technology, the Restful Jaw ®. The ... the patient’s jaw while minimizing jaw pain, fatigue and ... can experience shorter treatment times when patients do not ... pain. , The Restful Jaw is a vital ...
(Date:7/22/2014)... HealthDay Reporter MONDAY, July 21, 2014 (HealthDay ... asthma appears to offer relief to people with chronic hives ... The prescription drug -- omalizumab (Xolair) -- is already ... approval earlier this year for that use. The current ... dose for a six-month period it seems to be both ...
(Date:7/22/2014)... at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute ... one of the most complex and difficult-to-treat forms ... , Locally advanced pancreatic cancer has the lowest ... cumulative five-year survival rate of only 4 percent ... an option for patients because tumors often involve ...
Breaking Medicine News(10 mins):Health News:CyraCom Ranked Among the World’s Largest Language Service Providers 2Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 2Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 3Health News:Introducing the Restful Jaw – The Only Device Designed to Protect the Patient’s Jaw 2Health News:Introducing the Restful Jaw – The Only Device Designed to Protect the Patient’s Jaw 3Health News:Asthma Drug May Help Those With Chronic Hives 2Health News:Asthma Drug May Help Those With Chronic Hives 3Health News:Unique study focuses on combined treatment approach for locally advanced pancreatic cancer 2Health News:Unique study focuses on combined treatment approach for locally advanced pancreatic cancer 3
... Health Plans Offer Broader ChoiceEAGAN, Minn., April 13 ... today announced the largest array of individual health plan ... buy health insurance on their own. The new plans ... series of "design your own health plan" sessions, in ...
... 13 The American Heart Association, with support from ... three research centers to study the development and mechanisms ... next four year, the centers will be conducting studies ... help improve outcomes for heart attack and heart failure ...
... 5,000 years ago , , MONDAY, April 13 (HealthDay News) -- ... stomach,s sake," may have been heeded more than 5,000 years ... residues found in wine jars left in the tomb of ... had been steeped in herbs including balm, coriander, mint and ...
... Jean Nordin Evans, DDS, FIND and Dr. Robert Evans, DMD, FIND, FAGD ... new medical center located at Mill Run Plaza. , ... Groton, MA ... visionary, announced today that Groton Wellness Medical Center has opened its doors ...
... beyond mere placebo effect , , MONDAY, April 13 (HealthDay ... a 25 percent less nausea during radiation treatments, a new ... Journal of Pain and Symptom Management , also discounted ... as a placebo than an actual pain reliever. , ...
... 13 The Advertising Council, in partnership,with Autism Speaks, ... public,service advertisements (PSAs) featuring professional golfer Ernie Els, and ... about autism and to urge,parents to learn the early ... in every 150 children. , , ...
Cached Medicine News:Health News:Blue Cross Launches Largest Selection of Individual Plans Available in Minnesota 2Health News:Blue Cross Launches Largest Selection of Individual Plans Available in Minnesota 3Health News:Three Medical Centers Awarded Funds to Study Generation of Cardiac Muscle Cells 2Health News:Pharoah's Wine Jar Yields Medicinal Secrets 2Health News:Pharoah's Wine Jar Yields Medicinal Secrets 3Health News:Top Medical and Dental Team Opens Groton Wellness Medical Center in Groton, MA 2Health News:Top Medical and Dental Team Opens Groton Wellness Medical Center in Groton, MA 3Health News:Top Medical and Dental Team Opens Groton Wellness Medical Center in Groton, MA 4Health News:Wristbands May Lessen Nausea After Radiation 2Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 2Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 3Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 4
... Intersurgical Incorporated manufactures high ... and moisture exchangers, ventilator ... hand-held nebulizers and an ... and connectors for anesthesia ...
... line has the right product for any ... from intubated patients to patients with tracheotomies. ... anesthesia and critical care applications., ,The ... for patients and staff members. This entire ...
... (HCH) capture the patient`s exhaled heat and ... gas. Small and compact, they are specially ... Depending on the tidal volume requirements, select ... ,The adult HCH is ideal for patient ...
... These hygroscopic condenser humidifiers (HCH) capture ... return them in the inspired gas. Small ... provide bacteriostatic and hygroscopic benefits. Depending on ... adult or small-volume model., ,The adult ...
Medicine Products: